Le Lézard
Classified in: Health
Subjects: MAV, EXE, NTA, FVT

/R E P E A T -- Notice to the Media - MP Robert-Falcon Ouellette to participate in event to applaud First Nation Foot Care Program/

OTTAWA, Oct. 5, 2017 /CNW/ - On behalf of the Honourable Jane Philpott, Minister of Indigenous Services, and the Honourable Ginette Petitpas Taylor, Minister of Health, Robert-Falcon Ouellette, Member of Parliament for Winnipeg Centre, will participate in an event to applaud the newly created First Nation Basic Foot Care Program.

October 6, 2017

11:30 a.m. CDT

(First Nations Health and Social Secretariat of Manitoba)
17th floor boardroom
275 Portage Avenue
Winnipeg, Manitoba


SOURCE Health Canada

These press releases may also interest you

at 08:03
Systemic sclerosis is a rare, serious chronic autoimmune disease with no approved therapyAffects approximately 90,000 individuals in US and EU and associated with 10-year mortality of 40-60%Corbus Pharmaceuticals Holdings, Inc. ("Corbus" or the...

at 08:03
Golden Leaf Holdings Ltd. ("GLH" or the "Company") , a leading cannabis oil solutions company and dispensary operator built around recognized brands, today announced that it has opened a new Chalice Farms dispensary on the popular Willamette River...

at 08:02
Geneia (www.Geneia.com), an analytic solutions and services company that is simplifying the evolution to value-based care, announced its new partnership with Salesforce Health Cloud to better serve the needs of health plans, hospitals, providers and...

at 08:00
The HealthWell Foundation®, an independent non-profit that provides a financial lifeline for inadequately insured Americans, has launched a new fund to provide copayment and premium assistance to Medicare patients living with acromegaly. Through the...

at 08:00
A Moody's Analytics report, prepared for the Blue Cross Blue Shield Association (BCBSA), was released today linking social determinants of health to differences in health across communities. Moody's Analytics utilized the Blue Cross Blue Shield...

at 08:00
Trovagene, Inc. , a precision medicine biotechnology company, engaged in the development of targeted cancer therapies, today announced the filing of its protocol for a Phase 2 clinical trial of PCM-075 in combination with abiraterone acetate (Zytiga®...

News published on 6 october 2017 at 07:00 and distributed by: